biostudies-literatureUnknown9(7)Wolach O<h4>Abstract</h4>Venetoclax plus hypomethylating agents are considered standard of care for patients with acute myeloid leukemia (AML) judged ineligible for intensive chemotherapy (IC). Real-world studies complement clinical trials, because patterns of patient selection, treatment exposure, and postremission management may vary. This prospective observational multicenter study included 209 newly diagnosed IC-ineligible patients with a median age 75 years (interquartile range, 71-81 years). A high proportion of patients had secondary AML (53.7%), adverse-risk disease (35.3%), and complex karyotype (15.5%). At a median follow-up of 22.5 months (range, 0.1-43), median overall survival (mOS) was 11.7 months (95% confidence interval [CI], 9.9,15.4). Composite complete remission was achieved in Blood advances1544-1554https://www.ebi.ac.uk/biostudies/studies/S-EPMC11986219biostudies-literatureTrial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.PMC11986219Stemer GLevi ICohen RBerelovich JFrankel NNachmias BHellmann IMoshe YZuckerman TOkasha DWolach OCanaani JBerger AJOfran YBleterman AAmitai IDally NTadmor TTavor SGanzel CGrunspan MBarak MfalseTrial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study.<h4>Abstract</h4>Venetoclax plus hypomethylating agents are considered standard of care for patients with acute myeloid leukemia (AML) judged ineligible for intensive chemotherapy (IC). Real-world studies complement clinical trials, because patterns of patient selection, treatment exposure, and postremission management may vary. This prospective observational multicenter study included 209 newly diagnosed IC-ineligible patients with a median age 75 years (interquartile range, 71-81 years). A high proportion of patients had secondary AML (53.7%), adverse-risk disease (35.3%), and complex karyotype (15.5%). At a median follow-up of 22.5 months (range, 0.1-43), median overall survival (mOS) was 11.7 months (95% confidence interval [CI], 9.9,15.4). Composite complete remission was achieved in 2025-01-01T00:00:00Z2025 Apr2026-06-01T13:09:51.405Z2025-07-12T03:04:08.772ZS-EPMC119862193963730710.1182/bloodadvances.2024014014